TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.

Kevin B Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.